Wednesday, July 8, 2026

Patent intelligence · US

US 7704527

Modified release compositions of milnacipran

granted A61KA61K31/165A61K9/2054A61K9/2846
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 4
Applicant portfolio 28
Patent details — US 7704527
Jurisdiction
US
Status
granted
Grant date
Apr 27, 2010
Expiration
Apr 22, 2030
Claims
17
CPC classes
A61K, A61K31/165, A61K9/2054, A61K9/2846
View on Google Patents ↗

Quick answer

US 7704527 (Modified release compositions of milnacipran) is held by Collegium Pharmaceutical, Inc.. Status: granted. Granted Apr 27, 2010. Expires Apr 22, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K31/165, A61K9/2054, A61K9/2846, A61P, A61P1/00

More from Collegium Pharmaceutical, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11191758

    Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors

    Uniwersytet Jagiellonski Collegium Medicum · Expires Dec 2, 2041

    granted
  2. US 10668060

    Tamper-resistant pharmaceutical compositions of opioids and other drugs

    Collegium Pharmaceutical, Inc. · Expires May 28, 2040

    granted
  3. US 10646485

    Process of making stable abuse-deterrent oral formulations

    Collegium Pharmaceutical, Inc. · Expires May 7, 2040

    granted
  4. US 10525052

    Abuse-deterrent drug formulations

    Collegium Pharmaceutical, Inc. · Expires Jan 2, 2040

    granted
  5. US 10525053

    Abuse-deterrent pharmaceutical compositions of opioids and other drugs

    Collegium Pharmaceutical, Inc. · Expires Jan 2, 2040

    granted
  6. US 10188644

    Process of making stable abuse-deterrent oral formulations

    Collegium Pharmaceutical, Inc. · Expires Jan 24, 2039

    granted
  7. US 10004729

    Tamper-resistant pharmaceutical compositions of opioids and other drugs

    Collegium Pharmaceutical, Inc. · Expires Jun 21, 2038

    granted
  8. US 9968598

    Process of making stable abuse-deterrent oral formulations

    Collegium Pharmaceutical, Inc. · Expires May 10, 2038

    granted

Frequently asked questions

What is US patent 7704527?

US 7704527 (Modified release compositions of milnacipran) is held by Collegium Pharmaceutical, Inc.. Status: granted. Granted Apr 27, 2010. Expires Apr 22, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7704527?

Collegium Pharmaceutical, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.

When does US 7704527 expire?

Our index shows an expiration date of Apr 22, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.